These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 9734550)
1. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Reimherr FW; Amsterdam JD; Quitkin FM; Rosenbaum JF; Fava M; Zajecka J; Beasley CM; Michelson D; Roback P; Sundell K Am J Psychiatry; 1998 Sep; 155(9):1247-53. PubMed ID: 9734550 [TBL] [Abstract][Full Text] [Related]
2. Efficacy in long-term treatment of depression. Montgomery SA J Clin Psychiatry; 1996; 57 Suppl 2():24-30. PubMed ID: 8626360 [TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. Schmidt ME; Fava M; Robinson JM; Judge R J Clin Psychiatry; 2000 Nov; 61(11):851-7. PubMed ID: 11105738 [TBL] [Abstract][Full Text] [Related]
4. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Berman RM; Darnell AM; Miller HL; Anand A; Charney DS Am J Psychiatry; 1997 Jan; 154(1):37-43. PubMed ID: 8988956 [TBL] [Abstract][Full Text] [Related]
5. A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. Romano SJ; Halmi KA; Sarkar NP; Koke SC; Lee JS Am J Psychiatry; 2002 Jan; 159(1):96-102. PubMed ID: 11772696 [TBL] [Abstract][Full Text] [Related]
6. Fluoxetine once every third day in the treatment of major depressive disorder. Tural U; Onder E Eur Arch Psychiatry Clin Neurosci; 2003 Dec; 253(6):307-12. PubMed ID: 14714120 [TBL] [Abstract][Full Text] [Related]
7. Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. Romano S; Goodman W; Tamura R; Gonzales J J Clin Psychopharmacol; 2001 Feb; 21(1):46-52. PubMed ID: 11199947 [TBL] [Abstract][Full Text] [Related]
8. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Nierenberg AA; McLean NE; Alpert JE; Worthington JJ; Rosenbaum JF; Fava M Am J Psychiatry; 1995 Oct; 152(10):1500-3. PubMed ID: 7573590 [TBL] [Abstract][Full Text] [Related]
9. Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression. McGrath PJ; Stewart JW; Petkova E; Quitkin FM; Amsterdam JD; Fawcett J; Reimherr FW; Rosenbaum JF; Beasley CM J Clin Psychiatry; 2000 Jul; 61(7):518-24. PubMed ID: 10937611 [TBL] [Abstract][Full Text] [Related]
12. A double-blind, randomized study to provide safety information on switching fluoxetine-treated patients to paroxetine without an intervening washout period. Kreider MS; Bushnell WD; Oakes R; Wheadon DE J Clin Psychiatry; 1995 Apr; 56(4):142-5. PubMed ID: 7713852 [TBL] [Abstract][Full Text] [Related]
13. Fluoxetine in the prevention of depressive recurrences: a double-blind study. Gilaberte I; Montejo AL; de la Gandara J; Perez-Sola V; Bernardo M; Massana J; Martin-Santos R; Santiso A; Noguera R; Casais L; Perez-Camo V; Arias M; Judge R; J Clin Psychopharmacol; 2001 Aug; 21(4):417-24. PubMed ID: 11476126 [TBL] [Abstract][Full Text] [Related]
14. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. Tollefson GD; Birkett M; Koran L; Genduso L J Clin Psychiatry; 1994 Oct; 55 Suppl():69-76; discussion 77-8. PubMed ID: 7961535 [TBL] [Abstract][Full Text] [Related]
15. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Bauer M; Bschor T; Kunz D; Berghöfer A; Ströhle A; Müller-Oerlinghausen B Am J Psychiatry; 2000 Sep; 157(9):1429-35. PubMed ID: 10964859 [TBL] [Abstract][Full Text] [Related]
16. Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Stewart JW; Quitkin FM; McGrath PJ; Amsterdam J; Fava M; Fawcett J; Reimherr F; Rosenbaum J; Beasley C; Roback P Arch Gen Psychiatry; 1998 Apr; 55(4):334-43. PubMed ID: 9554429 [TBL] [Abstract][Full Text] [Related]
17. Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up. Fruehwald S; Gatterbauer E; Rehak P; Baumhackl U J Neurol; 2003 Mar; 250(3):347-51. PubMed ID: 12638027 [TBL] [Abstract][Full Text] [Related]
18. Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Rabkin JG; Wagner GJ; Rabkin R Am J Psychiatry; 1999 Jan; 156(1):101-7. PubMed ID: 9892304 [TBL] [Abstract][Full Text] [Related]
19. Effect of fluoxetine on dexamethasone-induced growth hormone release in depression: a double-blind, placebo-controlled study. Thakore JH; Dinan TG Am J Psychiatry; 1995 Apr; 152(4):616-8. PubMed ID: 7694914 [TBL] [Abstract][Full Text] [Related]
20. A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia. Hellerstein DJ; Yanowitch P; Rosenthal J; Samstag LW; Maurer M; Kasch K; Burrows L; Poster M; Cantillon M; Winston A Am J Psychiatry; 1993 Aug; 150(8):1169-75. PubMed ID: 8328559 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]